Product Description
For Parkinson's Disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01171313)
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: XenoPort
Company Location: REDWOOD CITY CA 94063
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Parkinson's Disease
Recent News Events
Date |
Type |
Title |
|---|